Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer
NCT ID: NCT02494869
Last Updated: 2025-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
75 participants
INTERVENTIONAL
2015-07-31
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The participant will be instructed to self-report the session information to ExOnc staff at or before their next scheduled visit. If the participant's next scheduled visit is greater than 72 hours following an unsupervised session, ExOnc staff may reach out to the participant to retrieve the session information. Unsupervised session details will be source documented by ExOnc staff.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exercise, Fitness and Tumor Profiling in Breast Cancer Patients
NCT03424915
Aerobic Training in Metastatic Breast Cancer
NCT01725633
Study on Breast Cancer Patient Perspectives of Exercise
NCT02559362
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
NCT06322888
Acute Exercise Intervention in Breast Cancer Survivors
NCT03779867
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nonlinear Aerobic Training (75 minutes/week) closed to accrual
The ultimate goal is for participants to complete 75 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the (CPETs performed at baseline, midpoint, and Study Follow-Up. The 75 min/wk will be achieved via 3 individual supervised aerobic training sessions at approximately 25 minutes/session.All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study. This arm is closed to accrual.
Nonlinear Aerobic Training
Height, Weight, BMI measure
Blood draw
Cardiopulmonary exercise test
Nonlinear Aerobic Training (150 minutes/week)
The ultimate goal is for participants to complete 150 minutes/week of structured aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from the CTPETs test performed at baseline, midpoint, and Study Follow-Up. The 150 minutes/week will be achieved by completing 3 aerobic training sessions/week for approximately 50 minutes/session. All other on- site participants in Arms A and B will be provided with a heart rate monitor to thank them for completing the study.
Nonlinear Aerobic Training
Height, Weight, BMI measure
Blood draw
Cardiopulmonary exercise test
Nonlinear Aerobic Training (300 minutes/week)
The ultimate goal is for participants to complete 300 minutes/week of aerobic training per week at 55% to 100% of the individually determined exercise capacity (VO2peak) determined from CPETs performed at baseline, midpoint, and Study Follow-Up. The 300 minutes/week will be achieved by completing 5 aerobic training sessions/week for approximately 60 minutes/session. A minimum of 3 sessions/week are required to be supervised while the remaining 2 sessions can be supervised or unsupervised home-based. Participants on all Arms will receive a heart rate monitor prior to beginning unsupervised home-based aerobic training sessions. Vital sign monitoring guidelines for unsupervised sessions, prescribed at lower intensities, will be advised by the exercise physiologist at the time the session plan is provided to the patient. Patients will be instructed to not begin an unsupervised session if their resting heart rate or blood pressure is outside the recommended guidelines.
Nonlinear Aerobic Training
Height, Weight, BMI measure
Blood draw
Cardiopulmonary exercise test
General Physical Activity
Usual care patients will receive a home-based, general physical activity program. Specifically, all patients assigned to general physical activity will receive an initial, in-person consultation with staff exercise physiologist outlining a structured home-based aerobic walking program with a goal up to 150 minutes per week outside of their normal daily activity. Patients can be provided with a fitness tracker (e.g. FitBit) to evaluate exercise duration and intensity. Patients may also be provided with an exercise log to records type, duration, and average heart rate during sessions. The exercise log is provided as a guidance tool and may be, although is not required to be, returned to study staff. Staff exercise physiologists will contact patients to check progress and answer questions.
Blood draw
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nonlinear Aerobic Training
Height, Weight, BMI measure
Blood draw
Cardiopulmonary exercise test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cytologically confirmed atypical hyperplasia
* Cytologically confirmed LCIS
* Being a carrier for
* BRCA1 and/or BRCA2
* Predicted lifetime risk of breast cancer \>20% based on family history)
* Predicted 10-year risk of breast cancer of ≥ 2.31%
* Predicted 5-year risk of breast cancer ≥ 1.67%
* Aged 21 ≤ 80 years old
* If a female of child-bearing potential, must not be pregnant or planning to become pregnant during the study.
* Women \<50 years old who are of child-bearing potential must have a negative pregnancy test (urine HCG or serum) within 14 days of enrollment.
* Must a negative mammogram or negative breast MRI within 1 year of protocol required baseline core biopsy
* Clinical breast exam interpreted as benign (not suspicious for cancer) at MSK
* Performing less than or equal to 120 minutes of structured moderate-intensity or strenuous-intensity exercise per week
* Able to complete an acceptable baseline CPET in the absence of high risk ECG findings or other inappropriate response to exercise as determined by the investigator.
* Able to achieve an acceptable peek baseline CPET defined as by any of the following criteria:
* achieving a plateau in oxygen consumption concurrent an with increase in power output;
* a respiratory exchange ratio ≥ 1.10;
* attainment of maximal predicted heart rate (HRmax) (i.e., within 10 bpm of age-predicted \[HRmax = 220-Age\[years\]) Volitional exhaustion, as measured by a rating of perceived exertion (RPE) ≥ 18 on the BORG scale.
Exclusion Criteria
* Enrollment on an interventional investigational study
* Bilateral breast implants
* Any newly identified breast abnormality requiring surgical excision
* History of any of the following:
* Invasive cancer diagnosis
* DCIS
* Any current invasive cancer diagnosis
* Metastatic malignancy of any kind
* Any other condition or intercurrent illness that in the opinion of the investigator makes the subject a poor candidate for core biopsy or the trial
* Mental impairment leading to inability to cooperate.
* Room air desaturation at rest ≤85%
* Any of the following absolute contraindications to cardiopulmonary exercise testing and/or aerobic training:
* Acute myocardial Infarction (within 3-5 days of any planned study procedures);
* Unstable angina;
* Uncontrolled arrhythmia causing symptoms or hemodynamic compromise;
* Recurrent syncope;
* Active endocarditis;
* Acute myocarditis or pericarditis;
* Symptomatic severe aortic stenosis;
* Uncontrolled heart failure;
* Acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures;
* Thrombosis of lower extremities;
* Suspected dissecting aneurysm;
* Uncontrolled asthma;
* Pulmonary edema;
* Respiratory failure;
* Acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis); or
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Memorial Sloan Kettering Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jessica Scott, PhD
Role: PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Memorial Sloan Kettering Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-093
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.